Site Network Renew with clinicalRSVP.com's Research Participant Registry
clinicalRSVP.com, the participant registry that prevents research volunteers from enrolling in overlapping and concurrent research studies, announced that all seven (7) sites making up the original clinicalRSVP user network, including Clinical Pharmacology of Miami (one site), Comprehensive Clinical Development (three sites), Elite Research Institute (one site), and Seaview Research Inc. (two sites), have agreed to extend their commitment to the clinicalRSVP network through 2012 and beyond.
In 2009, this group of sites was the first in North America to adopt a subject registry for the purpose of preventing dual enrollment, thereby increasing data integrity and participant safety for their clients. Since inception, the clinicalRSVP network has grown to include 18 Phase I Units across the United States and Canada, representing more than 20 percent of the North American Phase I beds.
With ever-growing support from sponsors and sites alike, the mission of clinicalRSVP.com is to provide a single North American registry for investigators to confidentially and securely verify subject eligibility requirements prior to enrollment, thereby improving data integrity for sponsors and trial safety for participants.
“Ensuring our participants’ safety and facilitating rapid study start-up are the primary focuses for us at Comprehensive Clinical Development,” said Dr. Rae DelVecchio, Senior Vice President, Early Phase Operations. “We want our sponsors and participants to have total confidence in every aspect of our business and clinicalRSVP is a key component of our enrollment process.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
